In this article, we will list the 5 Best Stocks Under $10 Offering More Than 50% Upside. Please visit 10 Best Stocks Under $10 Offering More Than 50% Upside if you’d like to see an extended list and the methodology behind it.
5. SAB Biotherapeutics Inc. (NASDAQ:SABS)
SAB Biotherapeutics Inc. (NASDAQ:SABS) is one of the 10 best stocks under $10 offering more than 50% upside.
On June 24, Eliana Merle from Barclays initiated coverage of SAB Biotherapeutics Inc. (NASDAQ:SABS) with a target price of $13, and assigned an Overweight rating to the stock. As per Merle’s projections, the stock currently offers a highly lucrative upside potential of more than 235%.
Image: Depositphotos
According to Merle, SAB-142 has a substantial opportunity as a potential disease-altering treatment in the type 1 diabetes marketplace. The analyst believes that the Phase 2b data, which is anticipated in the latter half of 2027, will be the primary driver for the stock.
Following the recent approval of Tzield, she views the regulatory process for SAB-142 as de-risked. Merle noted that the anticipated $4 billion potential for SAB-142, as a type 1 diabetes therapy, is not fully reflected in the company’s current market capitalization of $300 million.
Back on May 22, Citi also initiated its coverage of the stock with a target price of $11, yielding an upside potential in excess of 184% at the prevailing level. The firm assigned a Buy rating to the stock, based on its view that the company is redefining the broader landscape for type 1 diabetes cure. The firm also acknowledged SAB’s efforts toward immune modulation based on a “clinically validated” framework.
SAB Biotherapeutics Inc. (NASDAQ:SABS) is a clinical-stage biopharmaceutical company that focuses on the development of human polyclonal immunotherapeutic antibodies. Its main product candidate is SAB-142 for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials.
4. Verastem Inc. (NASDAQ:VSTM)
Verastem Inc. (NASDAQ:VSTM) is one of the 10 best stocks under $10 offering more than 50% upside.
On June 24, Verastem Inc. (NASDAQ:VSTM) revealed encouraging initial findings from the ongoing TARGET-D 101 Phase 1/2 trial of VS-7375. It is an experimental oral KRAS G12D inhibitor for patients with advanced KRAS G12D-mutated tumors. The results showed encouraging clinical activity and a satisfactory tolerance and safety profile within several dosage levels and tumor types. These included metastatic colorectal cancer, advanced non-small cell lung cancer, and metastatic pancreatic ductal adenocarcinoma.
According to Verastem Oncology’s President of Development, Michael Kauffman, VS-7375 showed anti-tumor effectiveness across a range of dosages and malignancies. Data also indicated positive outcomes from combination strategies and a favorable safety profile after the first treatment cycle. It also demonstrated concordance when used alongside anti-EGFR therapy and conventional chemotherapy, encouraging its development across colorectal, pancreatic and lung malignancies.
The company plans to enroll patients in three Phase 2 registration-directed trials as a follow-up to the TARGET-D 101 study, and it anticipates sharing further VS-7375 results at the end of this year.
Verastem Inc. (NASDAQ:VSTM) is a development-stage biopharmaceutical company involved in developing and commercializing drugs for the treatment of cancer. Its product candidates are Avutometinib, FAKZYNJA, Defactinib, VS-7375, CO-PACK, and AVMAPKI. The company is involved in clinical studies of RAMP 301, RAMP 205, FRAME, VS-7375-101, RAMP 203, and RAMP 201.
3. Wave Life Sciences Ltd. (NASDAQ:WVE)
Wave Life Sciences Ltd. (NASDAQ:WVE) is one of the 10 best stocks under $10 offering more than 50% upside.
On June 24, Wave Life Sciences Ltd. (NASDAQ:WVE) began the Phase 2a multidose part of the INLIGHTTM trial. The study aims to assess WVE-007, an experimental GalNAc-siRNA, as a monotherapy in people with obesity (BMI 35–50 kg/m²) and associated comorbidities in this placebo-controlled (3:1) study.
An ongoing Phase 1 single-dose component of the INLIGHT trial is examining WVE-007 in normal, healthy people who are on the verge of obesity and have an average BMI of 32 kg/m². A sole 240 mg dose of WVE-007 sustained to produce clinically significant decreases in waist circumference (-3%), visceral fat (-14%; p<0.05), and total fat (-5%) at six months of follow-up in this section of the experiment.
Data suggest the possibility of a once or twice yearly dosage of WVE-007, which is still typically tolerable as well as safe up to 600 mg. Additional changes in human body composition, such as weight loss, enhanced biomarkers of cardiometabolic health, and increased fat loss with retained muscle, are anticipated in Phase 2a of the INLIGHT trial.
Wave Life Sciences Ltd. (NASDAQ:WVE) is involved in the development and commercialization of ribonucleic acid (RNA) medicines, focusing on RNA editing, splicing, and silencing. The company leverages its technology platform, PRISM, which ensures precision targeting of diseases and improvement of pharmacological properties through stereopure oligonucleotides.
2. Inventiva S.A. (NASDAQ:IVA)
Inventiva S.A. (NASDAQ:IVA) is one of the 10 best stocks under $10 offering more than 50% upside.
As of the June 24 close, Inventiva S.A. (NASDAQ:IVA) had a strongly bullish consensus sentiment. The stock received Buy ratings from all 9 analysts who provided coverage. Based on a 1-year median price target of $15.75, it currently offers a huge upside potential of over 325%.
On June 12, Inventiva S.A. (NASDAQ:IVA) shared updates on some of its recently announced financing arrangements. The company fully repaid roughly €62 million of its existing EIB loans, which included the principal amount and accrued interest on the loans.
The company also executed a buyback and subsequent cancellation of its warrants linked to around 22.7 million EIB shares. This included all Tranche A warrants and 700,000 Tranche B warrants, adding up to a total repurchase price of €50 million.
The company also carried out a €75 million drawdown through debt financing with its lenders, i.e., Claret Capital Partners and BlackRock. This included an amount of €35 million in Tranche A Senior Secured Convertible Debt and €40 million in Tranche B Senior Secured Amortized Debt.
Conversion price applicable on Tranche A Convertible Bonds is €5.2893, representing a 40% premium on the EURO-denominated offer price for the stock ADS.
Inventiva S.A. (NASDAQ:IVA) is a clinical-stage biopharmaceutical company. The company is focused on developing oral small-molecule therapies in France and worldwide. It develops Odiparcil and Lanifibranor. The company is also involved in the development of TGF-ß, which is used for treating idiopathic pulmonary fibrosis.
1. Voyager Therapeutics Inc. (NASDAQ:VYGR)
Voyager Therapeutics Inc. (NASDAQ:VYGR) is one of the 10 best stocks under $10 offering more than 50% upside.
Back on June 1, Voyager Therapeutics Inc. (NASDAQ:VYGR) received FDA approval for VY1706, a gene therapy for Alzheimer’s that targets extracellular and intracellular tau. The company had previously submitted an Investigational New Drug (IND) application, and this recent clearance will allow Voyager to begin VY1706 clinical trials on individuals with preliminary symptoms of Alzheimer’s. Dosages are projected to start during the last 6 months of 2026.
The company CEO, Alfred W. Sandrock, reflected favorably on this development that followed a thorough preclinical process. He emphasized how reducing tau can be a crucial step in curing Alzheimer’s. Sandrock stated:
“The IND clearance for VY1706 is the first for a tau-targeted gene therapy and follows a comprehensive preclinical program demonstrating a compelling pharmacology and safety profile. Recent third-party data continue to suggest that tau is the next critical target in Alzheimer’s disease, and that reducing tau production holds promise. We view VY1706 as leading the next generation of tau targeting treatments; it is designed to durably reduce tau protein levels in key brain regions following a single IV administration.”
The company shared that siRNA is the core of VY1706 and targets MAPT mRNA to lower extracellular and intracellular tau levels in the brain. As a vectorized core, it is embedded into a TRACER AAV capsid that utilizes ALPL to direct siRNA towards the brain.
Voyager Therapeutics Inc. (NASDAQ:VYGR) is a biotechnology company. It is involved in human genetics to cure neurological diseases. The product pipeline offered by this company includes VY1706, TRACER, ALPL-VYGR-NeuroShuttle, and VY7523. The company also offers a research program to cure Huntington’s disease.
While we acknowledge the potential of VYGR to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than VYGR and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 12 Oversold Financial Stocks to Invest in According to Hedge Funds.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
